This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Kathryn A. Bayles, PhD; Cheryl K. Tomoeda, MS, CCC-SLP; Jody A. Wood; Erwin B. Montgomery, Jr, MD; Robyn F. Cruz, PhD; Tamiko Azuma, PhD; Anna McGeagh, MEd

Arch Neurol. 1996;53(11):1140-1146.

Abstract
Objective
To study the effects of Parkinson disease (PD) on cognitive function by determining the frequency and amount of change in Mini-Mental State Examination (MMSE) performance.

Design
During a 4-year period, 77 patients with idiopathic PD and 43 normal elders were administered a neuropsychological test battery twice at 2 years apart.

Results
A 4-point score difference on the MMSE was the amount that was statistically calculated to be a significant difference at the.05 probability level. Using this metric, 17 (22%) patients with PD had a change in their MMSE performance during a 2-year period. Fifteen individuals performed poorer, and 2 individuals improved. Using the same metric, no normal subjects changed in their MMSE performance. The groups of patients with PD who had a change and did not have a change in their MMSE performance were not characterized by significant differences in their years of education, duration of illness, age at onset, age at test time 1, estimated premorbid intelligence, Hamilton Psychiatric Rating Scale for Depression score at test time 1, or Unified Parkinson's Disease Rating Scale score. The singular difference was the higher frequency of change that was found in subjects who were taking dopamine agonists at the second test time.

Conclusion
A change in cognitive function in patients with PD, as measured by a change of 4 points or more in their MMSE performance, was observed in only 22% of a sample of 77 patients with idiopathic PD during a 2-year period.

Author Affiliations
From the Departments of Speech and Hearing Sciences (Dr Bayles) and Neurology (Dr Montgomery) and the National Center for Neurogenic Communication Disorders (Drs Bayles, Cruz, and Azuma and Mss Tomoeda, Wood, and McGeagh), University of Arizona Main Campus and College of Medicine, Tucson.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Rate of Cognitive Decline in Parkinson Disease
Aarsland et al.
Arch Neurol 2004;61:1906-1911.
ABSTRACT | FULL TEXT  

Predictors of cognitive impairment in advanced Parkinson's disease
Vingerhoets et al.
J. Neurol. Neurosurg. Psychiatry 2003;74:793-796.
ABSTRACT | FULL TEXT  

Are Late-Onset Schizophrenia Spectrum Disorders Neurodegenerative Conditions? Annual Rates of Change on Two Dementia Measures
Palmer et al.
J. Neuropsychiatry Clin. Neurosi. 2003;15:45-52.
ABSTRACT | FULL TEXT  

Neuropsychological follow up in patients with Parkinson's disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy
Soliveri et al.
J. Neurol. Neurosurg. Psychiatry 2000;69:313-318.
ABSTRACT | FULL TEXT